How Does Chemotherapy Kill Cancer?

Before answering the question 'how does chemotherapy kill cancer? it is worth quickly discussing the differences and similarities between a cancerous cell and a non-cancerous cell in a human being.

The chief difference between a cancerous cell and a non-cancerous cell is that the cancerous cell has acquired a genetic mutation in its DNA that has allowed the cell to avoid scheduling and carrying out its own death—a process known as apoptosis. Healthy cells die when they are supposed to die; unhealthy or cancerous cells do not. This is the most general definition of cancer one can imagine.

MITOSIS, OR CELL DIVISION

Cells divide in a five part process known as mitosis. These five parts, known as cell cycles, constitute the times when a cell is at its most vulnerable to chemotherapy, because various chemotherapy drugs work by throwing a wrench of sorts into the process. That 'wrench' stops mitosis in its tracks and leads to the death of the cell.

For this reason, fast-growing or aggressive cancers tend to respond the best to chemotherapy because these cancers are made of cells that undergo mitosis frequently, making them vulnerable far more often to chemotherapy than other cells.

CHEMOTHERAPY AS A SYSTEMIC TREATMENT

Traditional chemotherapy acts in a systemic manner. This means that the drugs are applied to the entire body even if a patient's cancer is found to be in a confined region of the body. Chemotherapy drugs are administered in such a fashion that this can't be prevented with standard chemo drugs—such as through an IV. This helps explain the existence of the many side effects associated with chemotherapy. It kills cancer cells and it kills healthy cells. The cells it will kill will be the fast-growing healthy cells—such as those in the mouth and digestive system, the blood, and the hair follicles, among other places.

Combination chemotherapy, such as the CHOP regimen, are created and tested with the understanding that each of the drugs will attack the cell cycle in a different way, the hope being to kill as many of the cancerous cells as possible.

THE FUTURE OF CHEMOTHERAPY

The development of chemotherapy began several decades ago when the US government began testing chemical after chemical to see if it had any anti-cancer activity. It has evolved now to the point where scientists and researchers are focusing on treatments that are progressively less systemic and decidedly more targeted, so that they preserve more healthy cells and cause fewer side effects. One direction is in immunotherapy, while others include variations on immunotherapy and radiology, such as the Zevalin therapeutic regimen.

However, chemotherapy isn't going anywhere any time soon, as despite the side effects, it still provides many patients with effective anti-cancer care.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap